Introduction
Abnormal uterine bleeding is the most classical initial manifestation of primary and/or secondary endometrial neoplasia. Breast cancer is the most common extra-gynecologic secondary source of endometrial neoplasia by being the main primary site that metastasizes to the uterus, especially lobular type. Tamoxifen therapy has been shown to be an excellent treatment option for patients with estrogen receptor (ER) positive breast cancer. Despite its promising results, its well-established mixed agonist/antagonist estrogenic effects can provoke endometrial hyperplasia, subsequently increasing the risk of endometrial cancer.

Case report
A 69-year-old female with a clinical history significant for grade 2 invasive lobular carcinoma (ILC) of the breast status post modified radical mastectomy in 2013, and currently on tamoxifen therapy presented in June 2018 to her obstetrician/gynecologist (OBGYN) with complaints of post-menopausal bleeding. Pelvic ultrasound (U/S) showed a poorly defined and thickened endometrium without distinct lesions. Endometrial biopsy was performed showing fragments of endometrial stroma infiltrated by a single-cell and sheet-like proliferation of deeply basophilic, medium-sized cells with focal signet ring-like features (Figure 1(a) and (b)) suggestive of metastatic disease.

Immunohistochemical (IHC) stains showed these cells to be positive for CK AE1/AE3, CAM5.2, GATA-3, mamma-globin and ER (Figure 2(a)–(e)), confirming the diagnosis of metastatic mammary carcinoma, consistent with her known history of ILC.

Discussion
Metastases from extra-gynecologic primary sites to the uterus are infrequent, with breast and the colon being the most common sites. On the contrary, ovarian tumors are by
Figure 1. Endometrial biopsy (H&E): (a) sheets of deeply basophilic cells (low power) and (b) cells with signet ring-like features (arrow) (high power).

Figure 2. Endometrial biopsy (IHC): cells staining positive for (a) CK AE1/AE3, (b) CAM5.2, (c) GATA-3, (d) mammaglobin, and (e) ER.
far the most common gynecologic primary site to metastasize to the uterus. Mazur et al. studied the anatomic localization of metastases in the uterine corpus and concluded that involvement of the endometrium itself accounted for 3.8% of the cases, both the myometrium and endometrium 32.7%, and myometrium only 63.5%. Of the cases limited to the endometrium, ILC is the most predominant histologic type, and given the site, these tumors are more likely to present with abnormal uterine bleeding than those arising in the myometrium only. A case report and literature review made by Razia et al. summarize the incidence of metastatic breast carcinoma specifically to leiomyomas. A total of 8 out of a total of 14 cases (57.1%) consisted of ductal carcinoma, while lobular carcinoma comprised 6/14 (42.9%), which included their current case, and less than a half of all the cases presented with uterine bleeding.

According to G Le Bouèdec et al., seven out of eight cases of uterine metastasis of breast origin were ILC type with a commonly positive hormone receptor status. The authors also noted that the breast metastasis occurs many years after the initial diagnosis. C Alvarez et al. reported a case of hormone receptive metastatic ILC to the uterus presenting in a post-menopausal patient 4 years after initial treatment. Exceptional cases, including the case reported by H Trihia et al., might occur 19 years after initial diagnosis. A Aytekin et al., S Dessole et al., and A Famoriyo et al. have also reported hormone receptive metastatic ILC in patients treated with tamoxifen therapy.

Invasive ductal carcinoma (IDC) and ILC are the two most frequent histologic subtypes of breast cancer. IDC accounts for approximately 76% of all breast cancers while ILC accounts for 8%. Despite its lower incidence, ILC is the most likely histologic subtype to metastasize to the female genital tract. It has been proposed that this phenomenon is due to the small size of the ILC tumor cells, and their loss of expression of their cell–cell adhesion molecule E-cadherin, which confers them a discohesive property resulting in cell adhesion alterations, which is not seen in IDC. The presence of abundant signet ring-like cells, as in our case, was not considered specific for ILCs as it may be seen in the setting of IDC as well. In addition, it has been proven that metastatic breast carcinomas with signet ring cell differentiation do not represent a distinct entity by itself, and no specific prognosis is believed to be associated with signet ring cell differentiation. The overlapping morphologic features of the background endometrial stromal cells with the single-cell and sheet-like proliferation of the metastatic tumor cells was a major diagnostic challenge in our case, especially that both cell types are likely to demonstrate positivity for hormone receptors. However, the positivity for both epithelial markers CAM 5.2 and CK AE1/AE3 as well as the breast origin sensitive markers GATA3 and mammaglobin in the tumor cells helped in reaching the correct diagnosis.

Tamoxifen is the most widely used oral anti-breast cancer drug. It is a nonsteroidal drug that acts as a selective estrogen receptor modulator (SERM) in the breast, thus representing an excellent option for the treatment of hormone receptor positive breast cancer. Paradoxically, it acts as an estrogen agonist in other tissues, mainly the endometrium, promoting epithelial thickening. Tamoxifen is metabolized by a series of enzymes in the liver, including CYP2D6, which further breaks it into other compounds. Gene polymorphisms affecting the activity of this enzyme might explain why some patients have a better response to tamoxifen compared with others.

O Metzger et al. presented the “BIG 1-98 trial” in September 2015, comparing the effectiveness of tamoxifen (ER antagonist) versus Letrozole (aromatase inhibitor) in ILC patients. Letrozole showed a better reduction in the disease burden and increased disease-free survival events compared with tamoxifen. These results created confusion about the best first line therapy for ILC. In 2014, Dr Jankowitz R launched a new national study, in collaboration with the translational breast cancer research consortium, which objective is to compare the efficacy of three endocrine therapies: fulvestrant, tamoxifen, and anastrozole in treating ILC. Outcomes are still to be reported.

Conclusion

Endometrial metastasis from a breast primary poses a significant diagnostic challenge given its low incidence rate. A complete diagnostic workup to rule out metastatic disease should be warranted when confronted with complaints of abnormal uterine bleeding, especially in patients with a known history of carcinoma, regardless of its location.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Our institution does not require ethical approval for reporting individual cases or case series.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iD

Mariangela Gomez https://orcid.org/0000-0001-7346-201X

References

1. Kumar NB and Hart WR. Metastases to the uterine corpus from extragenital cancers: a clinicopathologic study of 63 cases. Cancer 1982; 50(10): 2163–2169.
2. Mazur MT, Hsueh S and Gersell DJ. Metastases to the female genital tract: analysis of 325 cases. Cancer 1984; 53(9): 1978–1984.
3. Barakat RR. Tamoxifen and endometrial neoplasia. *Clin Obstet Gynecol* 1996; 39: 629–640.
4. Razia S, Nakayama K, Tsukao M, et al. Metastasis of breast cancer to an endometrial polyp, the cervix and a leiomyoma: a case report and review of the literature. *Oncol Lett* 2017; 14(4): 4585–4592.
5. Le Bouedec G, de Latour M, Kauffmann P, et al. Uterine metastases originating from breast cancer. *Arch Anat Cytol Pathol* 1993; 41(3–4): 140–144.
6. Alvarez C, Ortiz-Rey JA, Estevez F, et al. Metastatic lobular breast carcinoma to an endometrial polyp diagnosed by hysteroscopic biopsy. *Obstet Gynecol* 2003; 102(5 Pt 2): 1149–1151.
7. Trihia H, Gavresea T and Novkovic N. Lobular carcinoma metastasis to endometrial polyp 19 years after primary diagnosis: a report of an exceptional case. *J Clin Obstet Gynecol Infertil* 2017; 1(4): 1019.
8. Aytekin A, Bilgetekin I and Ciltas A. Lobular breast cancer metastasis to uterus during adjuvant tamoxifen treatment: a case report and review of the literature. *J Cancer Res Ther* 2018; 14(5): 1135–1137.
9. Dessole S, Cherchi PL and Ruiu GA. Uterine metastases from breast cancer in a patient under tamoxifen therapy. *Eur J Gynaecol Oncol* 1999; 20(5–6): 416–417.
10. Famoriyo A, Sawant S and Banfield PJ. Abnormal uterine bleeding as a presentation of metastatic breast disease in a patient with advanced breast cancer on tamoxifen therapy. *Arch Gynecol Obstet* 2004; 270(3): 192–193.
11. Li CI, Uribe DJ and Daling JR. Clinical characteristics of different histologic types of breast cancer. *Br J Cancer* 2005; 93(9): 1046–1052.
12. Ferlicot S, Vincent-Salomon A, Medioni J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. *Eur J Cancer* 2004; 40(3): 336–341.
13. Harris M, Howell A, Chrissohou M, et al. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. *Br J Cancer* 1984; 50(1): 23–30.
14. Lakhani S, Ellis I, Schnitt S, et al. *WHO classification of tumours of the breast*. 4th ed. Lyon: IARC Press, 2012.
15. Goetz MP, Rae JM and Suman VJ. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. *J Clin Oncol* 2005; 23(36): 9312–9318.
16. Metzger Filho O, Giobbie-Hurder A, Mallon E, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. *J Clin Oncol* 2015; 33(25): 2772–2779.